Kadant CFO Michael J. McKenney sells $2.8 million in stock

Published 03/03/2025, 22:18
Kadant CFO Michael J. McKenney sells $2.8 million in stock

Michael J. McKenney, Executive Vice President and Chief Financial Officer of Kadant Inc . (NYSE:KAI), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, McKenney sold a total of 9,026 shares of Kadant’s common stock on February 28, 2025. The transactions were executed at various prices ranging from $368.00 to $377.50 per share, amounting to approximately $2.8 million in total proceeds. The sales come as Kadant trades at relatively high valuation multiples, with a P/E ratio of 39.4 and an EV/EBITDA of 20.1.

The sales were conducted in multiple transactions, with notable sales including 1,617 shares at an average price of $368.64 per share, 3,945 shares at $369.71 per share, and 875 shares at $372.84 per share. Following these transactions, McKenney retains ownership of 11,314 shares in the company. The stock has shown strong momentum, delivering a 23.7% return over the past six months.

Kadant Inc., headquartered in Westford, Massachusetts, is a leading provider of engineered systems used in process industries. The company is listed on the New York Stock Exchange under the ticker KAI. With a market capitalization of $4.4 billion and annual revenue of $1.05 billion, Kadant maintains strong financial health according to InvestingPro analysis, which offers comprehensive insights and 12 additional ProTips for this stock.

In other recent news, Kadant Inc. reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.25, compared to the forecasted $2.08. The company also achieved a revenue of $258 million, slightly exceeding the anticipated $257.85 million. These results reflect Kadant’s strong performance in aftermarket parts, which contributed 66% of the total revenue for the year. In addition to its financial achievements, Kadant has been included in the S&P SmallCap 600 index, following the acquisition of Inari Medical (TASE:BLWV) by Stryker Corp (NYSE:SYK). This inclusion is expected to enhance Kadant’s visibility and liquidity in the market. Furthermore, the company has provided revenue guidance for 2025, projecting figures between $1.040 billion and $1.065 billion, with adjusted EPS expected to range from $9.70 to $10.05. Analysts from William Blair have shown interest in Kadant’s capital project plans and have been monitoring the company’s strategic positioning for future growth. As Kadant continues to navigate economic uncertainties, the company remains focused on sustainability and operational efficiency.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.